|Mr. Douglas A. Hamilton B.Sc., MBA||Pres, Chief Exec. Officer & Director||260k||N/A||51|
|Mr. Daniel H. Schneiderman||VP of Fin., Controller & Sec.||165k||N/A||39|
|Mr. Frederick E. Pierce II||VP of Investor Relations||N/A||N/A||N/A|
|Dr. Michael J. Donovan Ph.D., M.D.||Acting Chief Medical Officer||N/A||N/A||N/A|
|Dr. Heinrich Dreismann Ph.D.||Diagnostic Consultant||N/A||N/A||62|
MetaStat, Inc., a biotechnology company, focuses on discovering and developing personalized therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel therapeutic product candidates that target the Mena protein isoform driver-based diagnostic biomarkers; companion tests to be used in combination with cancer drugs, which provide information for the safe and effective use of a corresponding drug or biological product; and diagnostic tests that predict the risk of future metastasis in cancer patients following initial treatment of their primary tumor. Its product candidates include MenaINV assay for use as both a companion diagnostic and prognostic diagnostic; MenaCalc assay, a prognostic diagnostic for patients with early stage invasive breast cancer; and MetaSite Breast assay, a tissue-based immunohistochemistry assay that identifies and quantifies the sites of metastatic process. The company is based in Boston, Massachusetts.
MetaStat, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.